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Abstract   40 
OBJECTIVE: To assess the outcome of patients with advanced ovarian cancer (OC) who were 41 
treated without surgery, having received upfront chemotherapy and no interval debulking surgery 42 
(IDS).   43 
METHODS: Retrospective analysis of medical and chemotherapy records of consecutive patients 44 
with OC between 2005 and 2013 at UCL Hospitals London, UK who received neoadjuvant 45 
chemotherapy (NACT) and were then found to be unsuitable for IDS following review by the 46 
multidisciplinary team.  47 
RESULTS: Eighty-three patients (18%) out of 467 receiving NACT did not undergo IDS. Median 48 
age was 70 years (range 33–88); 51.8% presented with stage IV disease. Forty-three patients 49 
received carboplatin and paclitaxel (CP) (51.8%) and 37 received carboplatin alone (C) (44.6%); 3 50 
(3.6%) patients received other platinum-based combinations. Reasons for not proceeding to surgery 51 
were: poor response to chemotherapy after 3-4 cycles of NACT (61/83, 73.5%); comorbidities 52 
(12/83, 14.5%); patient decision (4/83, 4.8%). Six patients (7.2%) received < 3 cycles of NACT due 53 
to a worsening clinical condition.  The median overall survival (OS) for patients not undergoing IDS 54 
was 18 months (95% CI 10–20 months). Forty-four (53%) patients received > 2 lines of 55 
chemotherapy. In a univariate analysis CP, age < 70 years, and absence of comorbidities were 56 
factors influencing OS.  In a multivariate analysis only having received CP remained independently 57 
associated with OS (HR 0.49, 95% CI 0.29-0.84). 58 
CONCLUSIONS Chemotherapy alone can provide reasonable disease control in patients unsuitable 59 
for IDS and CP should be used if possible. 60 
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INTRODUCTION 74 
Epithelial Ovarian Carcinoma (EOC) is the leading cause of death from gynecological cancer in the 75 
Western World. For women presenting with advanced disease the 5-year survival rate is 76 
approximately 30%[1]. Survival of women with epithelial ovarian cancer has improved partly as a 77 
consequence of more aggressive surgery to achieve optimal cytoreduction, the use of platinum-78 
based treatment and better treatment of recurrent disease [2]. Nonetheless, approximately 80% of 79 
patients who present with advanced disease develop progression or relapse and die within 5 years 80 
from diagnosis[3]. 81 
Optimal primary debulking surgery followed by platinum-based chemotherapy [3] is the 82 
recommended treatment for advanced ovarian cancer (FIGO III–IV). Neoadjuvant chemotherapy 83 
(NACT) followed by interval debulking surgery (IDS) can be considered an alternative first-line 84 
treatment for patients in whom primary cytoreductive surgery is not possible or contraindicated due 85 
to co-morbidity [4-6]. Recent studies have shown similar outcome to primary surgery when interval 86 
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debulking surgery (IDS) is performed after three cycles of neoadjuvant chemotherapy followed by 87 
three post-IDS cycles of chemotherapy [4-6]. 88 
It has been estimated that in 10-25 % [6-8] of patients surgical debulking may be not feasible even 89 
after NACT, due to poor response to chemotherapy, poor or worsening of performance status, 90 
significant co-morbdities, or patients desire to avoid extensive surgery that might require bowel 91 
resection. 92 
For these women chemotherapy is the primary treatment. It is usually given with palliative intent but 93 
little is known about the outcome of these patients 94 
The aim of this retrospective study was to understand the natural history of patients with advanced 95 
stages of EOC, treated with chemotherapy alone. 96 
 97 
MATERIALS AND METHODS 98 
All women with a diagnosis of invasive EOC who were treated between January 2005 and 99 
December 2013 at UCL Hospitals, London UK were included in this audit. Data were collected 100 
between October and November 2014 by reviewing the medical records, radiological imaging, 101 
chemotherapy prescriptions and outcome information. 102 
The inclusion criteria were as follows: (1) histologically confirmed diagnosis of epithelial ovarian 103 
cancer; (2) not suitable for primary or interval debulking surgery; (3) having received primary 104 
chemotherapy and (4) availability of medical records.  105 
Staging was performed radiologically and defined in accordance with the FIGO (International 106 
Federation of Gynecology and Obstetrics) classification for ovarian cancer. All patients had 107 
previously undergone histological review by a specialist in gynaecological pathology. Patients with 108 
a borderline tumor or a non-epithelial tumor were excluded.  109 
All patients were treated with platinum-based chemotherapy and underwent radiological evaluation 110 
after 3 or 4 cycles of chemotherapy.  They were assessed for surgery by the Multidisciplinary Team. 111 
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Criteria for a poor response and consequently unsuitability for surgery were defined as follows: 112 
diffuse deep infiltration of the root of the small bowel mesentery, widespread bowel serosal 113 
involvement, multiple parenchymatous liver metastases, infiltration of the duodenum and/or 114 
pancreas and/or the large vessels of the hepatic-duodenal ligament, celiac trunk or behind the porta 115 
hepatis, multiple lung metastases.  116 
The medical charts were reviewed to obtain information on the reason for not undergoing surgery, 117 
the type of first line chemotherapy, dates of treatment and the reasons for dose reductions and 118 
delays.  The Charlson Comorbidity index (CCI) score [9] was used retrospectively to assess co-119 
morbidity.  120 
Response was assessed by physical examination, serial measurement of CA125, and computed 121 
tomographic imaging. Response at the end of treatment was assessed by CA125 according to GCIG 122 
criteria [10] and radiological  assessment (computed tomographic scan). Progression was defined by 123 
clinical or radiological findings and the time to progression was taken as the date of radiological 124 
evidence of progression.  Further treatments were recorded and overall survival was calculated from 125 
the date of primary diagnosis to date of death or to last follow-up visit for the patients still alive. 126 
Median follow-up period was measured from the date of primary diagnosis to the time of last 127 
follow-up visit.  128 
Chi-square or Fisher’s exact test was used for comparison of categorical variables.  A logistic 129 
regression model was applied to determine the effect of independent variables (age, grading, 130 
presence of comorbidities (CCI)/ pulmonary embolism, stage, and histology) on the choice of 131 
chemotherapy. Survival was calculated using the Kaplan–Meier method. Log-rank test was used to 132 
compare survival between groups. Multivariate analysis for prognostic factors was performed by 133 
Cox’s proportional hazards regression model. All P values were two-sided, and the p-value was set 134 
at 0.05. All statistical calculations were carried out using SPSS for Mac version 22.0 (SPSS Inc., 135 
USA).  136 
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RESULTS 140 
During the study period primary chemotherapy was given to 467 patients with ovarian cancer and 83 141 
patients (18%) did not proceed to surgery, and are the subject of this study.  142 
The median age was 70 years (range 33–88 years). Two age categories were defined: 70 years old or 143 
younger, and greater than 70 years old: the median age was 61 years (range 33–70) in the former,  144 
and 79 years (range 71–88) in the latter. Clinical and pathological characteristics of patients are 145 
described in table 1. Ten patients (12%) had previous history of other cancers. Patients in the older 146 
group were more frequently affected by comorbidities (according to CCI), 65.9% compared to 147 
45.2% in the younger patients; Forty-three patients (51.8%) had stage IV disease and  10 patients 148 
(19.3%) presented with a pulmonary embolism (PE), or developed a PE during chemotherapy (5 149 
patients).  150 
Paclitaxel and carboplatin were given to   43 patients (51.8%) and 37 received carboplatin alone  151 
(44.6%); three patients (3.6%) received other platinum –based combinations. The median number of 152 
cycles given was 6 (range 1-8), and 24% of patients received less than 6 cycles. Five patients also 153 
received bevacizumab (6.3%). Patients older than 70 years (OR 0.31, CI95% 0.10-0.93, p= 0.007) 154 
and those presenting with at least one comorbidity (OR 0.31, CI95% 0.10-0.90, p= 0.016) were 155 
more likely to receive carboplatin alone treatment rather than carboplatin plus paclitaxel.  156 
Six patients (7.2%) received less than 3 cycles of chemotherapy, stopping because of a worsening 157 
clinical condition, and were therefore not assessable for IDS  (table 2).  158 
Sixty-one patients (73.5%) out of the whole group were judged to be unsuitable for optimal surgical 159 
debulking on the basis of a poor response to chemotherapy. Other reasons for having not having 160 
surgery were patient decision (4/83, 4.8%) and the presence of comorbidities in 12/83, 14.5%). The 161 
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comorbidities were severe cardiovascular disease (CVD) (7 patients), a cerebrovascular accident 162 
(CVA) (1 patient) and significant worsening pulmonary embolus (8 patients), including 4 patients 163 
with CVD or CVA. 164 
At the end of chemotherapy 53 patients (63.8 %) had a partial response on CT imaging, 12 (14.4%) 165 
had stable disease and ten (12%) patients had disease progression. In 2 patients radiological 166 
information was absent (2.4 %) and 6 patients were not assessable for IDS, as stated above. 167 
According to CGIG criteria, among the 59 patients whose CA125 measurements were available and 168 
evaluable, 50 (84.7%) had a response, including 17 (28.8%) with a complete response, whilst there 169 
were 6 (10.1%) who did not achieve any response and 3 were not evaluable (CA 125 below normal 170 
range at diagnosis). 171 
Thirty-nine out of 83 patients (46.9%) received only one line of chemotherapy; 24 (28.9%) patients 172 
received a second line of chemotherapy following disease progression. Subsequently, 15 patients 173 
(18%) received 3 lines, 2 patients (2.4%) received 4 lines, 1 patient (1.2%) received 5 lines and 2 174 
patients (2.4%) received 6 lines of chemotherapy. Overall, 44 (53%) patients received > 2 lines of 175 
chemotherapy. 176 
The median follow-up period was 18 months. The median OS of the overall population was 18 177 
months (95% CI 10–20 months). 178 
Analysing OS according to type of chemotherapy received in the overall population (Fig. 1), women 179 
who underwent carboplatin plus paclitaxel had better median OS of 27 (95% CI 20–33 months) 180 
months compared with 15 (95% CI 14–19 months) months for patients who received carboplatin 181 
alone (log rank: p=0.002; HR 0.45, 95% CI 0.27- 0.75). 182 
In a univariate analysis (table 3), type of chemotherapy (carboplatin vs. carboplatin plus paclitaxel) 183 
and age (> or < 70 years), and absence of comorbidities were factors influencing OS.  However, in 184 
the multivariate analysis (table 3) only treatment with the combination of carboplatin plus paclitaxel 185 
was independently associated with OS (log rank: p=0.002; HR 0.49, 95% CI 0.29-0.84). 186 
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DISCUSSION 189 
Debulking surgery to remove all residual disease remains the cornerstone of ovarian cancer 190 
treatment [11]. Nonetheless, even in clinical trials of NACT in patients with potentially 191 
operable disease, 10-25% are not able to undergo debulking surgery [6,7]. There is little 192 
information about the outcome of this group of women. The key finding was that 18% of all 193 
patients in our institution undergoing primary chemotherapy do not undergo surgery and 194 
their median survival was 18 months. A poor response to chemotherapy was the main reason 195 
for failure to proceed to surgery and in 27% the decision was made not to operate because of 196 
co-morbidity or patient choice. However, 68.8% patients achieved a partial response to 197 
chemotherapy, 53% received a further line of chemotherapy, and 24 % had 3 or more lines of 198 
treatment. 199 
The median age of our population was 70 years, higher than the population median age of EOC at 200 
diagnosis [3]. Co-morbidity is more common in older patients so they are more likely to receive 201 
single agent carboplatin chemotherapy. Both age ≥70 years and CCI score ≥1 were independent 202 
predictors of single agent chemotherapy. This is in accordance with other experiences [12]. 203 
Although carboplatin and paclitaxel are considered as standard of treatment for stage II–IV ovarian 204 
cancer [13], single agent carboplatin compares well to a carboplatin plus paclitaxel combination [14] 205 
and it has been proposed that it is an acceptable standard treatment for older patients [15].  206 
We found that receiving the combination of carboplatin and paclitaxel is independently associated 207 
with better survival, even after adjusting for age and comorbidities. This underlines the importance 208 
of identifying which factors should preclude the use of paclitaxel in elderly patients. 209 
Approximately half of our patients received two or more lines of treatment. Whilst surgery plays a 210 
key role in the management of ovarian cancer, patients unable to undergo surgery should still be 211 
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considered for active management as in some of them, multiple lines of treatment are able to control 212 
the disease for many months. In our series, though we did not have information on symptom control 213 
or quality of life, the administration of several lines of chemotherapy contributed to the finding of a 214 
median OS of 18 months, which compares favourable to other reported series in which the median 215 
OS was in the range of 8-11 months [8,14-17] for patients unsuitable for surgery. Shalowitz et al 216 
recently reported a shorter OS for those who only received systemic treatment (12 months), and an 217 
even shorter OS for those who did not receive any treatment (1.4 months); unfortunately data about 218 
treatment administered and number of chemotherapy lines are lacking and further comparisons are 219 
not possible.  Overall, we might speculate that the availability of different combinations of treatment 220 
we described can provide some of these women with the opportunity of extended palliation without 221 
surgery as they can   receive several lines of treatment in the absence of surgery. 222 
The present study was a single institution retrospective investigation. Whilst consecutive patients 223 
were included, a selection or referral bias could have occurred, and this might have influenced the 224 
analyses, particularly the comparison of single agent and combination therapy.  Nonetheless we 225 
believe that our findings provide useful and relevant information to decision-making about surgery 226 
for clinicians treating patients with neoadjuvant therapy. Cytoreductive surgery remains the 227 
cornerstone of treatment of advanced EOC but when it cannot be performed chemotherapy provides 228 
good palliation and disease control for many patients.  229 
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FIGURE 297 
Figure 1 :  Overall survival of patients receiving  carboplatin alone (37 patients) or carboplatin plus 298 
paclitaxel (43 patients)  (log rank: p=0.003)  299 
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